

HR 7537

Infectious Disease Therapies Research and Innovation Act of 2020

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Taxation

Introduced: Jul 9, 2020

Current Status: Referred to the House Committee on Ways and Means.

Latest Action: Referred to the House Committee on Ways and Means. (Jul 9, 2020)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/7537>

Sponsor

Name: Rep. Kelly, Mike [R-PA-16]

Party: Republican • **State:** PA • **Chamber:** House

Cosponsors

No cosponsors are listed for this bill.

Committee Activity

Committee	Chamber	Activity	Date
Ways and Means Committee	House	Referred to	Jul 9, 2020

Subjects & Policy Tags

Policy Area:

Taxation

Related Bills

Bill	Relationship	Last Action
116 HR 14	Related bill	Nov 2, 2020: Referred to the Subcommittee on Railroads, Pipelines, and Hazardous Materials.

Summary (as of Jul 9, 2020)

Infectious Disease Therapies Research and Innovation Act of 2020

This bill exempts from the definition of *passive activity*, for purposes of the passive loss tax rules, any qualified medical research activity of a specified medical research small business pass-thru entity.

The bill defines *specified medical research small business pass-thru entity* as any domestic pass-thru entity if more than 80% of such entity's expenditures on research are paid or incurred in connection with qualified medical research activities and the gross receipts of such entity for the taxable year are less than \$1 million.

Actions Timeline

- **Jul 9, 2020:** Introduced in House
- **Jul 9, 2020:** Referred to the Subcommittee on Health.
- **Jul 9, 2020:** Referred to the House Committee on Ways and Means.